8. References:
1. Abbas, O., D.D. Miller, and J. Bhawan, Cutaneous malignant melanoma: update on diagnostic and prognostic biomarkers. Am J Dermatopathol, 2014. 36 (5): p. 363-79.
2. Brunssen, A., et al., Impact of skin cancer screening and secondary prevention campaigns on skin cancer incidence and mortality: A systematic review. J Am Acad Dermatol, 2017. 76 (1): p. 129-139.e10.
3. Prevention, C.f.D.C.a. United States Cancer Statistics: Incidence of Malignant Melanoma of the Skin—United States, 2009–2018. USCS Data Brief, no 28, 2022.
4. Luke, J.J., et al., Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet, 2022.399 (10336): p. 1718-1729.
5. Larkin, J., et al., Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238. Clin Cancer Res, 2023.
6. Poklepovic, A.S. and J.J. Luke, Considering adjuvant therapy for stage II melanoma. Cancer, 2020. 126 (6): p. 1166-1174.
7. Pavri, S.N., et al., Malignant Melanoma: Beyond the Basics.Plast Reconstr Surg, 2016. 138 (2): p. 330e-340e.
8. Long, G.V., et al., Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol, 2022. 23 (11): p. 1378-1388.
9. Kwok, G., et al., Pembrolizumab (Keytruda). Hum Vaccin Immunother, 2016. 12 (11): p. 2777-2789.
10. Wu, Z., et al., Establishing a Prognostic Model Based on Ulceration and Immune Related Genes in Melanoma Patients and Identification of EIF3B as a Therapeutic Target. Front Immunol, 2022.13 : p. 824946.
11. Niebling, M.G., et al., The prognostic significance of microsatellites in cutaneous melanoma. Mod Pathol, 2020.33 (7): p. 1369-1379.
12. Tas, F. and K. Erturk, Neurotropism as a prognostic factor in cutaneous melanoma patients. Neoplasma, 2018. 65 (2): p. 304-308.
13. Thomas, N.E., et al., Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study.J Clin Oncol, 2013. 31 (33): p. 4252-9.
14. Marchetti, M.A., et al., Performance of Gene Expression Profile Tests for Prognosis in Patients With Localized Cutaneous Melanoma: A Systematic Review and Meta-analysis. JAMA Dermatol, 2020.156 (9): p. 953-962.
15. Marsavela, G., et al., Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression. Br J Cancer, 2022. 126 (3): p. 401-408.
16. Passarelli, A., et al., Immune system and melanoma biology: a balance between immunosurveillance and immune escape. Oncotarget, 2017.8 (62): p. 106132-106142.
17. Azimi, F., et al., Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol, 2012. 30 (21): p. 2678-83.
18. Gershenwald, J.E., et al., Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin, 2017. 67 (6): p. 472-492.
19. Amin, M.B., et al., AJCC cancer staging manual . Vol. 1024. 2017: Springer.
20. Dong, H., et al., Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med, 2002.8 (8): p. 793-800.
21. Herbst, R.S., et al., Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature, 2014.515 (7528): p. 563-567.
22. Tumeh, P.C., et al., PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature, 2014.515 (7528): p. 568-571.
23. Spranger, S., et al., Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma. Proceedings of the National Academy of Sciences, 2016. 113 (48): p. E7759-E7768.
24. Yousef, Z., et al., Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma. Journal for ImmunoTherapy of Cancer, 2021.9 (6): p. e002057.
25. Brandacher, G., et al., Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res, 2006. 12 (4): p. 1144-51.
26. Huang, S.J., et al., Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J Invest Dermatol, 2009. 129 (11): p. 2676-85.
27. Pandit, A.S., et al., Using topical imiquimod for the management of positive in situ margins after melanoma resection. Cancer Med, 2015. 4 (4): p. 507-12.
28. Wolf, I.H., et al., Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch Dermatol, 2005.141 (4): p. 510-4.
29. Scarfì, F., et al., The role of topical imiquimod in melanoma cutaneous metastases: A critical review of the literature. Dermatologic Therapy, 2020. 33 (6): p. e14165.
30. Cheraghlou, S., et al., Association of Treatment Facility Characteristics With Overall Survival After Mohs Micrographic Surgery for T1a-T2a Invasive Melanoma. JAMA Dermatol, 2021. 157 (5): p. 531-539.